Microbot Medical Inc. (NASDAQ:MBOT) Given Average Rating of “Moderate Buy” by Analysts

Microbot Medical Inc. (NASDAQ:MBOT) has been given an average rating of “Moderate Buy” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $6.6250.

Several research firms have commented on MBOT. Wall Street Zen raised Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Loop Capital set a $4.00 target price on Microbot Medical in a research report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research note on Friday, April 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a report on Tuesday, April 14th.

Institutional Trading of Microbot Medical

Several large investors have recently bought and sold shares of MBOT. Zacks Investment Management purchased a new stake in shares of Microbot Medical during the third quarter valued at approximately $33,000. CTC Alternative Strategies Ltd. purchased a new position in shares of Microbot Medical in the first quarter valued at $28,000. Squarepoint Ops LLC acquired a new stake in Microbot Medical during the 3rd quarter valued at $37,000. American Century Companies Inc. acquired a new stake in Microbot Medical during the 2nd quarter valued at $32,000. Finally, Wexford Capital LP purchased a new stake in Microbot Medical during the 3rd quarter worth $50,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

Microbot Medical Stock Performance

Shares of MBOT stock opened at $1.86 on Friday. The company’s fifty day simple moving average is $1.90 and its 200-day simple moving average is $2.12. Microbot Medical has a 52 week low of $1.60 and a 52 week high of $4.67. The company has a current ratio of 22.59, a quick ratio of 21.93 and a debt-to-equity ratio of 0.01. The company has a market cap of $124.93 million, a PE ratio of -7.15 and a beta of 1.04.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities research analysts anticipate that Microbot Medical will post -0.31 EPS for the current year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.